+

WO2003013441A3 - Compositions de levothyroxine et procedes connexes - Google Patents

Compositions de levothyroxine et procedes connexes Download PDF

Info

Publication number
WO2003013441A3
WO2003013441A3 PCT/US2002/025475 US0225475W WO03013441A3 WO 2003013441 A3 WO2003013441 A3 WO 2003013441A3 US 0225475 W US0225475 W US 0225475W WO 03013441 A3 WO03013441 A3 WO 03013441A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
compositions
sodium
making
levothyroxine
Prior art date
Application number
PCT/US2002/025475
Other languages
English (en)
Other versions
WO2003013441A2 (fr
Inventor
G Andrew Franz
Elaine A Strauss
Phillip A Dimenna
Rocco L Gemma
Original Assignee
King Pharmaceuticals Inc
G Andrew Franz
Elaine A Strauss
Phillip A Dimenna
Rocco L Gemma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by King Pharmaceuticals Inc, G Andrew Franz, Elaine A Strauss, Phillip A Dimenna, Rocco L Gemma filed Critical King Pharmaceuticals Inc
Priority to AU2002332507A priority Critical patent/AU2002332507A1/en
Publication of WO2003013441A2 publication Critical patent/WO2003013441A2/fr
Publication of WO2003013441A3 publication Critical patent/WO2003013441A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention se rapporte d'une manière générale à des compositions pharmaceutiques stables et à des procédés de fabrication et d'administration de telles compositions. Selon une variante, l'invention se rapporte à des compositions pharmaceutiques stabilisées renfermant des principes pharmaceutiquement actifs, notamment du sodium de lévothyroxine (T4) et du sodium de liothyronine (T3) (médicaments d'hormone thyroïdienne), de préférence sous une forme solide à libération immédiate. Font également l'objet de cette invention des procédés de fabrication et d'utilisation de ces compositions stabilisées et à libération immédiate.
PCT/US2002/025475 2001-08-10 2002-08-10 Compositions de levothyroxine et procedes connexes WO2003013441A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002332507A AU2002332507A1 (en) 2001-08-10 2002-08-10 Levothyroxine compositions and methods

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US31154901P 2001-08-10 2001-08-10
US31152301P 2001-08-10 2001-08-10
US31155201P 2001-08-10 2001-08-10
US31152401P 2001-08-10 2001-08-10
US31152201P 2001-08-10 2001-08-10
US60/311,523 2001-08-10
US60/311,524 2001-08-10
US60/311,549 2001-08-10
US60/311,552 2001-08-10
US60/311,522 2001-08-10

Publications (2)

Publication Number Publication Date
WO2003013441A2 WO2003013441A2 (fr) 2003-02-20
WO2003013441A3 true WO2003013441A3 (fr) 2003-10-30

Family

ID=27540960

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/025475 WO2003013441A2 (fr) 2001-08-10 2002-08-10 Compositions de levothyroxine et procedes connexes

Country Status (2)

Country Link
AU (1) AU2002332507A1 (fr)
WO (1) WO2003013441A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7067148B2 (en) 2001-02-15 2006-06-27 King Pharmaceutical Research & Development, Inc. Stabilized pharmaceutical and thyroid hormone compositions and method of preparation
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7163918B2 (en) 2000-08-22 2007-01-16 New River Pharmaceuticals Inc. Iodothyronine compositions
US6645526B2 (en) 2001-11-13 2003-11-11 Mylan Pharmaceuticals, Inc. Storage stable thyroxine active drug formulations and methods for their production
US20030099699A1 (en) 2001-11-13 2003-05-29 Hanshew Dwight D. Storage stable thyroxine active drug formulations and methods for their production
US20060141054A1 (en) * 2004-10-25 2006-06-29 Thomas Piccariello Metal coordinated compositions
US8779175B2 (en) 2004-10-25 2014-07-15 Synthonics, Inc. Coordination complexes, pharmaceutical solutions comprising coordination complexes, and methods of treating patients
CN115078576B (zh) * 2022-06-14 2024-02-13 陕西九州制药有限责任公司 一种氨酚双氢可待因片有关物质的分析方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753254A (en) * 1994-02-01 1998-05-19 Knoll Aktiengesellschaft Therapeutic agents containing thyroid hormones
US5955105A (en) * 1995-11-14 1999-09-21 Knoll Pharmaceutical Company Stabilized thyroid hormone preparations and methods of making same
US6190696B1 (en) * 1998-06-08 2001-02-20 Pieter J. Groenewoud Stabilized thyroxine medications

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753254A (en) * 1994-02-01 1998-05-19 Knoll Aktiengesellschaft Therapeutic agents containing thyroid hormones
US5955105A (en) * 1995-11-14 1999-09-21 Knoll Pharmaceutical Company Stabilized thyroid hormone preparations and methods of making same
US6190696B1 (en) * 1998-06-08 2001-02-20 Pieter J. Groenewoud Stabilized thyroxine medications

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7067148B2 (en) 2001-02-15 2006-06-27 King Pharmaceutical Research & Development, Inc. Stabilized pharmaceutical and thyroid hormone compositions and method of preparation
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions

Also Published As

Publication number Publication date
AU2002332507A1 (en) 2003-02-24
WO2003013441A2 (fr) 2003-02-20

Similar Documents

Publication Publication Date Title
HK1096034A1 (en) A solid dosage form comprising a fibrate
WO2002017918A3 (fr) Formulations a liberation prolongee pour les secretagogues de l'hormone de croissance
BR0003158A (pt) Formulação de dosagem oral de derretimentoinstantâneo
BG66093B1 (bg) Състави с контролирано освобождаване, съдържащи нимесулид
PT1412384E (pt) Formulação estável de glp-1 modificado
MY151468A (en) Controlled release solid preparation
TW200505498A (en) Sugar-free oral transmucosal solid dosage forms and uses thereof
WO2002074247A8 (fr) Formulations pharmaceutiques a liberation prolongee
EA017764B8 (ru) Фармацевтическая композиция, способ ее получения и способ лечения вирусных заболеваний с ее использованием
MX2009003030A (es) Forma galenita para la administracion por via transmucosa de principios activos.
IL165601A0 (en) Oral pharmaceutical forms of liquid drugs having improved bioavailability
TW200633716A (en) Compositions and methods for stabilizing active pharmaceutical ingredients
AU2002231654A1 (en) Pharmaceutical paste comprising an acid-labile active ingredient
MY151470A (en) Controlled release solid preparation
EE03089B1 (et) Ibuprofeeni sisaldav kihisev ravimpreparaat ja selle valmistamise meetod
WO2003028624A3 (fr) Compositions de levothyroxine et procedes
IL150528A0 (en) Ibuprofen containing active agent preparation
AP2003002763A0 (en) Controlled release formulations for oral administration
CY1107295T1 (el) Σταθεροποιηση στερεων φορμουλων φαρμακων του θυρεοειδους
MX2010004556A (es) Formulacion farmaceutica de acido clavulanico.
MXPA03002807A (es) Estabilizacion de formulaciones solidas de farmacos.
MXPA06000332A (es) Nueva composicion farmaceutica solida que comprende amisulprida.
WO2002015933A3 (fr) Combinaison
WO2003013441A3 (fr) Compositions de levothyroxine et procedes connexes
BR0209155A (pt) Tablete farmacêutico tendo um teor de api elevado

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VN YU ZA ZM

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载